Glaxo’s Avandia Should Be Pulled From U.K., BMJ Says
This article is for subscribers only.
GlaxoSmithKline Plc’s Avandia diabetes treatment should be withdrawn from the market and never should have been approved, the British Medical Journal’s Editor-in-Chief Fiona Godlee wrote as European regulators prepare to review the drug’s safety.
The Commission on Human Medicines advised the U.K. drug regulator in July that Avandia should be pulled because the product’s risks outweigh its benefits, according to the journal, which today published an investigation of the drug with an editorial from Godlee.